Menu
Synergy in Action

Biomarkers Working Group Activity / Deliverables

Chairs: Steven Potkin, MD, Don Goff, MD
Objectives: CNS drug developers currently lack many of the tools necessary to implement the use of biomarkers in the later stages of the drug development process. Given this, and the burden of development and qualification of biomarkers in terms of both time and cost, the formation of collaborative international groups to undertake these biomarker related challenges is essential. These challenges provide a unique opportunity for meaningful industry-academia-government collaboration.
Publications:
Biomarkers for drug development in early psychosis: Current issues and promising directions
Goff DC, Romero K, Paul J, Perez-Rodriguez M, Crandall D, Potkin SG
European Neuropsychopharmacology 2016.01.009 (Public Access permission obtained)
Activity History:
2016 Autumn Biomarkers Conference Workshop Summary , 26 September 2016, Philadelphia, PA
Working Group Dinner Report Back Summary, 17 February 2015
2014 Autumn Workshop, 6 October 2014, Boston, MA
Working Group Dinner, 18 February 2014, Washington DC
2013 Autumn Workshop, 30 September 2013, Philadelphia, PA
Working Group Dinner
, 19 February 2013, Washington DC
Autumn 2012 Autumn Conference Workshop
21 February 2012 Biomarkers Working Group Session Plenary Report Back
Autumn 2012 Autumn Conference Workshop
21 February 2012 Biomarkers Working Group Session Plenary Report Back
2011 Autumn Conference Evaluating Biomarkers for Schizophrenia: Issues in Identification, Categorization and Evaluation Workshop

RETURN TO WORKING GROUP PAGE